Skip to main content
SpringerLink
Log in

Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

To investigate whether sodium fluoride (NaF) is able to prevent bone loss in patients treated with corticosteroids (Cs), we performed a randomized, double-masked, placebo-controlled trial with 44 Cs-treated patients without established osteoporosis, defined as the absence of previous peripheral fractures and vertebral deformities on radiographs. The effects of NaF (25 mg twice daily) and placebo on the bone mineral density (BMD) of the lumbar spine and hips were compared at baseline and at 6, 12, 18 and 24 months. After 2 years, the BMD of the lumbar spine had decreased in the placebo group by 3.0% (95% CI: −4.9% to −1.0%;p<0.01); in the NaF group there was a statistically insignificant increase in BMD of 2.2% (95% CI: −0.8% to +5.3%). The difference in the changes in BMD between the two groups was +5.2% (95% CI: +1.8% to +8.6%;p<0.01). In the hips, BMD had decreased after 2 years in both groups: in the placebo group by −3.0% (95% CI: −5.0% to −1.0%;p<0.05) and in the NaF group by 3.8% (95% CI: −6.1% to −1.5%;p<0.01). The difference in the changes in BMD between the two groups was not significant: +0.8% (95% CI: −2.1% to +3.8%). Three vertebral deformities were observed in the placebo group and one in the NaF group (insignificant difference), while no peripheral fractures occurred during the study period. It is concluded that in Cs-treated patients without established osteoporosis NaF prevents bone loss in the lumbar spine but does not have a positive effect on the BMD of the hips.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352–64.

    PubMed  CAS  Google Scholar 

  2. Adachi JD, Bensen WJ, Hodsman AB. Coricosteroid-induced osteoporosis. Semin Arthritis Rheum 1993;22:375–84.

    Article  PubMed  CAS  Google Scholar 

  3. Lems WF, Jacobs JWG, Bijlsma JWJ. Corticosteroid-induced osteoporosis. Rheumatology in Europe 1995;24(Suppl 2):76–9.

    Google Scholar 

  4. Dietrich JW, Canalis EM, Maine DM, Raisz G. Effects of glucocortcoids on fetal rat bone collagen synthesis in vitro. Endocrinology 1979;104:715–21.

    PubMed  CAS  Google Scholar 

  5. Meunier PJ, Dempster DW, Edouard C, Chapuy MC, Arlot M, Chardhon S. Bone histomorphometry in corticosteroid-induced osteoporosis in Cushing’ syndrome. Adv Exp Med Biol 1984;171:191–200.

    PubMed  CAS  Google Scholar 

  6. Nielsen HK, Brixen K, Kassem M, Mosekilde L. Acute effects of 1,25-dihydroxyvitamin D3 plus prednisone onserum osteocalcin in normal individuals. J Bone Miner Res 1991;6:435–41.

    PubMed  CAS  Google Scholar 

  7. Lems WF, Jacobs JWG, Rijn HJM van, Bijlsma JWJ. Changes in calcium and bone metabolism during treatment with low dose prednisone in young, healthy, male volunteers. Clin Rheumatol 1995;14:420–4.

    Article  PubMed  CAS  Google Scholar 

  8. Gennari C, Civitelli R. Glucocorticoid-induced osteoporosis. Clin Rheum Dis 1986;12:637–54.

    PubMed  CAS  Google Scholar 

  9. Prummel MF, Wiersinga WM, Lips P, Sanders GTB, Sauerwein HP. The course of biochemical parameters of bone turnover during treatment and corticosteroids. J Clin Endocrinol Metab 1991;72:382–6.

    Article  PubMed  CAS  Google Scholar 

  10. Lems WF, Veen GJM van, Gerrits MI, Jacobs JWG, Houben HHML, Rijn HJM van, Bijlsma JWJ. Effect of low dose prednisone on calcium and bone metabolism in healthy volunteers. Br J Rheumatol, in press.

  11. Dyckman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced ostopenia in patients with rheumatic diseases. Arthritis Rheum 1985;28:361–8.

    Article  Google Scholar 

  12. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990;150:2545–8.

    Article  PubMed  CAS  Google Scholar 

  13. Laan RFJM, Riel PCLM, Putte LBA van de, Erning LJThO van, Hof MA van’t, Lemmens JAM. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993;119:963–8.

    PubMed  CAS  Google Scholar 

  14. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265–8.

    Article  PubMed  CAS  Google Scholar 

  15. Lems WF, Jahangier ZN, Jacobs JWG, Bijlsma JWJ. Vertebral fractures in patients with rheumatoic arthritis treated with corticosteroid. Clin Exp Rheumatol 1995;13:293–7.

    PubMed  CAS  Google Scholar 

  16. Lau KHW, Farley JR, Baylink Dj. Phosphotyrosyl protein phosphatases. Biochemistry 1989;257:23–36.

    CAS  Google Scholar 

  17. Fakkeldij TMV, Damen CA, Duursma SA, Scheven BAA. Comparison of fluoride and vanadate effects on proliferation of human osteoblast-like calls in vitro. Calcif Tissue Int 1993;52[Suppl 1]:226.

    Google Scholar 

  18. Bayley TA, Muller C, Harrison J, Basualdo J, Sturtridge W, Josse R. The long-term treatment of steroid-osteoporosis with fluoride. J Bone Miner Res 1990;5[Suppl 1]:S157–61.

    PubMed  Google Scholar 

  19. Greenwald M, Brandli D, Spector S, Silverman S, Golde G. Corticosteroid-induced osteoporosis: effect of a treatment with slow-release sodium fluoride. Osteoporos Int 1992;2:303–4.

    Article  PubMed  CAS  Google Scholar 

  20. Rizzoli R, Chevalley T, Slosman DO, Bonjour JP. Monofluor-ophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporos Int 1995;5:39–46.

    Article  PubMed  CAS  Google Scholar 

  21. Bijlsma JWJ, Raymakers JA, Mosch C, Hoekstra A, Derksen RHWM, Baart de la Faille H, Duursma SA. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin Exp Rheumatol 1988;6:113–9

    PubMed  CAS  Google Scholar 

  22. Samsbrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J. Prevention of corticosteroid osteoporosis. N Engl J Med 1993;328:1747–52.

    Article  Google Scholar 

  23. Dyckman TR, Haralson KM, Gluck OS, et al. Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984;27:1336–43.

    Article  Google Scholar 

  24. Kleerekoper M, Parfitt AM, Ellis BI. Measurement of vertebral fracture rates in osteoporosis. In: Christiansen C, Arnaud CD, Nordin BEC, Parfitt AM, Peckn WA, Riggs BL, editors. Copenhagen International Symposium on Osteoporosis, 1984;103–9.

  25. Lems WF, Gerrits MI, Jacobs JWG, van Vugt RM, van Rijn HJM, Bijlsma JWJ. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:288–93.

    PubMed  CAS  Google Scholar 

  26. Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas PD, Measurement of serum osteocalcin with a human specific two-site immunoradiometric assay. J Bone Miner Res 1992;7:1389–98.

    PubMed  CAS  Google Scholar 

  27. Risteli J, Melkko J, Niemi S, Risteli L. Use of a marker of collagen formation in osteoporosis studies. Calcif Tissue Int 1991;49(Suppl):24–5.

    Article  Google Scholar 

  28. Risteli J, Niemi S, Elomaa I, Risteli L. Bone resorption assay based on a peptide liberated during type 1 collagen degradation. J Bone Miner Res 1991;6(Suppl 1):S251.

    Google Scholar 

  29. Gerrits MI, Thijssen JHH, Rijn HJM van. Determination of pyridinoline and deoxypyridinoline in urine, with special attention to retaining their stability. Clin Chem 1995;41:571–4.

    PubMed  CAS  Google Scholar 

  30. Mulder H, Struys A. Intermittent cyclical etidronate: the prevention of corticosteroid induced bone loss. Br J Rheumatol 1994;33:348–51.

    Article  PubMed  CAS  Google Scholar 

  31. Adachi JD, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividono A. Intermittent cyclic therapy with etridronate in the prevention of corticosteroid induced bone loss. J Rhuematol 1994;21:1922–6.

    CAS  Google Scholar 

  32. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235–42.

    Article  PubMed  CAS  Google Scholar 

  33. Meunier PJ, Sebert JL, Reginster JY, Avouac B, Briancon D, Fauquert P, et al. Fluoride salts compared to calcium-vitamin D in the treatment of established postmenopausal osteoporosis: the FAVOS study. Osteoporos Int 1996;6(Suppl 1):251.

    Article  Google Scholar 

  34. Lems WF, Jacobs JWG, Bijlsma JWJ, Veen GJM v, Houben HHML, Haanen HCM, Gerrits MI, Rijn HJM van. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid-induced osteoporosis? Ann Rheum Dis in press.

  35. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919–23.

    PubMed  CAS  Google Scholar 

  36. Mamelle N, Dusan R, Martin JL, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988;2:361–5.

    Article  PubMed  CAS  Google Scholar 

  37. Riggs BL, Hodgson SF, O’Fallon WM, Chao Eyes, Wahner HW, Muhs JM. et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802–9.

    Article  PubMed  CAS  Google Scholar 

  38. Rich C, Ensinck J, Ivanovich P. The effect of sodium fluoride on calcium metabolism of subjects with metabolic bone diseases. J Clin Invest 1964;43:545–56.

    Article  PubMed  CAS  Google Scholar 

  39. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Intern Med 1995;123:401–8.

    PubMed  CAS  Google Scholar 

  40. Gough AKS, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:3–27.

    Article  Google Scholar 

  41. Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993;34:797–801.

    Article  Google Scholar 

  42. Cummings SR, Black D. Bone mass measurements and risk of fracture on caucasian women: a review of findings from prospective studies. Am J Med 1995;98:s24–8.

    Article  Google Scholar 

  43. Cooper C, Kanis JA, Compston J. How to assess drug efficacy in osteoporosis. Lancet 1995;345:743–4.

    Article  PubMed  CAS  Google Scholar 

  44. Lindsay RL. Fluoride and bone, quantity versus quality. N Engl J Med 1990;322:845–6.

    Article  PubMed  CAS  Google Scholar 

  45. Riggs BL, Seeman E, Hodsgon SF, Taves DR, O’Fallon WM. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. N Engl J Med 1982;306:446–50.

    Article  PubMed  CAS  Google Scholar 

  46. Riggs BL, O’Fallon WM, Lane A, Hodgson SF, Wahnere HW, Muhs J. Clinical trial of fluroide therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 1994;9:265–75.

    PubMed  CAS  Google Scholar 

  47. Kleerekoper M. Fluoride: the verdict is in, but the controversy lingers. J Bone Miner Res 1996;11:565–7.

    PubMed  CAS  Google Scholar 

  48. Pak CYC, Zerwekh JE, Antich PP, Bell NH, Singer FR. Slow-release sodium fluoride in osteoporosis. J Bone Miner Res 1996;11:561–4.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology and Clinical Immunology F02.223, University Hospital Utrecht, PO Box 85500, 3508 CA, Utrecht, The Netherlands

    W. F. Lems MD, PhD, W. G. Jacobs & J. W. J. Bijlsma

  2. Department of Rheumatology, ‘de Wever’ Hospital, Heerlen

    A. Croone & H. H. M. L. Houben

  3. Department of Clinical Chemistry, Utrecht University Hospital, Utrecht

    M. I. Gerrits & H. J. M. van Rijn

  4. ‘St. Antonius’ ziekenhuis, Nieuwegein, The Netherlands

    H. C. M. Haanen

Authors
  1. W. F. Lems MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. G. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. W. J. Bijlsma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Croone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. C. M. Haanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. H. M. L. Houben
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. I. Gerrits
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. J. M. van Rijn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lems, W.F., Jacobs, W.G., Bijlsma, J.W.J. et al. Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporosis Int 7, 575–582 (1997). https://doi.org/10.1007/BF02652565

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02652565

Keywords

Search

Navigation